We propose that HDAC4 expression is closely associated with glioma grade and prognosis, with a lower HDAC4 expression significantly associated with progressive malignancy and unfavorable disease outcome, similar to what is observed in other cancers [41]. This evidence concerns the gene HDAC4 and central nervous system cancer.